Loading
Genetic Neurodegenerative Diseases / CRISPR and Genetic Engineering · Review
Medical Science · July 30, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of CRISPR-Cas9 approaches for Duchenne muscular dystrophy that reports preclinical restoration of dystrophin in animal models and identifies major clinical translation barriers—including immune responses to AAV vectors, off-target editing effects, and delivery to cardiac and respiratory muscle—without quantifying efficacy or safety in patients. The evidence base remains largely preclinical; the cited EMBARK trial is mentioned only qualitatively as demonstrating difficulty achieving long-lasting benefits.
Narrative systematic review. Duchenne muscular dystrophy patients (preclinical studies in animal models; EMBARK trial population not detailed). Intervention: CRISPR-Cas9 genome editing (exon skipping, frame-restoration, base editing, prime editing) for dystrophin restoration.
Preclinical studies show CRISPR-Cas9 can restore dystrophin via exon skipping or frame-restoration and decrease tissue degeneration in animal models Base and prime editing offer more precise correction with less likelihood of double-strand breaks than earlier cut-and-paste strategies EMBARK clinical trial results indicate patients face difficulty achieving long-lasting benefits from current approaches
EMBARK trial cited only descriptively; no efficacy or safety data provided
This review identifies CRISPR as a promising direction for permanent genetic correction but emphasizes that clinical translation remains early and fraught with safety and delivery barriers. Clinicians should view this as a research roadmap rather than evidence for current clinical practice; standard corticosteroid and palliative care remain the standard of care.
A narrative review synthesizing preclinical evidence and early clinical trial data to identify research directions, not reporting a primary empirical result with a defined effect size or comparator.
As stated by the source record.
This review identifies CRISPR as a promising direction for permanent genetic correction but emphasizes that clinical translation remains early and fraught with safety and delivery barriers. Clinicians should view this as a research roadmap rather than evidence for current clinical practice; standard corticosteroid and palliative care remain the standard of care.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Duchenne muscular dystrophy (DMD) is a rare progressive neuromuscular disorder caused by an absence of dystrophin that results in generalized muscle weakness and muscle wasting.DMD is inherited in an X-linked manner and results in irreversible loss of muscle tissue and early death.Standard treatment includes corticosteroids and palliative care, which help manage some symptoms without treating the actual genetic defect.CRISPR-Cas9 genome editing is a rapidly advancing area of neuromuscular research, with the potential to permanently fix the underlying genetic cause at the DNA level.In preclinical studies it has been shown that CRISPR technology can restore dystrophin through the use of methods such as exon skipping or frame-restoration, and thus decrease tissue degeneration due to dystrophin deficit.New advances in base and prime editing provide more precise methods for genetic correction and less likelihood of double-strand breaks than some previous-generation "cut-and-paste" gene-editing strategies.Nevertheless, shifting these methods from animal models to human therapies brings significant challenges.Considerations include the immune response to adeno-associated virus (AAV) vectors, the potential for off-target effects, and challenges with delivering the treatment to all muscle groups, most notably the heart joint and diaphragm.New clinical research, including the EMBARK clinical trial results, shows how difficult it is for patients to achieve long-lasting benefits.Despite these challenges, continued improvement in the accuracy of gene editing presents some hope that DMD will have an opportunity to be transitioned from a symptom management to a cure for the disease if current safety and delivery challenges can be overcome.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.